ReviewInternational journal of clinical oncology2026
The immunological paradox: immune checkpoint inhibitors in liver transplantation.
Review in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incorporation of immune checkpoint inhibitors (ICIs) into the treatment repertoire for hepatocellular carcinoma (HCC) and advanced biliary tract cancers has significantly transformed the field of oncology, offering remarkable survival advantages. However, the interaction of these powerful immunomodulators with liver transplantation (LT), the ultimate curative intervention for end-stage liver disease, presents a complex immunological paradox. While LT depends on the induction and maintenance of immune tolerance to suppress alloimmune responses and prevent allograft rejection, ICIs operate by disrupting these tolerance mechanisms to enhance host antitumor immunity. This comprehensive review synthesizes the latest evidence from 2024 and 2025, incorporating key findings from the VITALITY study, international washout cohorts, and meta-analyses of individual patient data. The historical "Liver Tolerance Effect," the mechanistic role of the PD-1/PD-L1 axis as a crucial protector of hepatic integrity, and the severe phenomenon of ICI-induced fatal hepatic necrosis are critically examined in this review. Furthermore, the emerging utility of precision predictive biomarkers, including immune-related adverse events (irAEs), the Eplet Risk Score, and intragraft PD-L1 expression as tissue-based predictors of post-transplant ICI-induced rejection, was rigorously analyzed to stratify rejection risk. By examining the pharmacodynamic conflict between systemic tumor eradication and localized graft preservation, this report provides a pragmatic, evidence-based framework for candidate selection, optimal washout timing, and post-transplant management, ultimately culminating in a critical appraisal of the ethical imperatives surrounding living donor liver transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.